Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26962000 | 0.85 | PDE4B (0.40) | SRCKCNH2MCHR1XIAPNPY1R | |
| SCHEMBL26961610 | 0.80 | NPC1 (0.43) | SRCXIAPNPY1RNPSR1TSHR | |
| SCHEMBL29797033 | 0.78 | SRC (0.42) | SRCXIAPNPY1RNPSR1TSHR | |
| SCHEMBL26962291 | 0.77 | SRC (0.37) | SRCXIAPNPY1RMAPT | |
| SCHEMBL26962177 | 0.77 | SRC (0.38) | SRCXIAPNPY1RMAPT | |
| SCHEMBL29796984 | 0.77 | SRC (0.38) | SRCXIAPNPY1RMAPT | |
| SCHEMBL29796737 | 0.77 | SRC (0.39) | SRCKCNH2MCHR1NPY1R | |
| SCHEMBL26961887 | 0.77 | SRC (0.39) | SRCKCNH2MCHR1NPY1R | |
| SCHEMBL29796900 | 0.75 | XIAP (0.33) | SRCXIAPNPY1RMAPT | |
| SCHEMBL26962007 | 0.75 | XIAP (0.33) | SRCXIAPNPY1RMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | SRC 2202/4885HCRTR1 83/4885HCRTR2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.